Residency · Residency · Medical Genetics Genomics
CRISPR-Based Therapeutics: From Bench to Bedside
Introduction
CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) has revolutionized genome editing by providing a programmable, efficient, and relatively simple tool for precise genetic modification. The transition from laboratory research to FDA-approved therapy occurred with remarkable speed, with the first CRISPR-based treatment approved in 2023. Understanding the technology, therapeutic applications, and challenges of clinical translation is essential for clinical geneticists.
CRISPR-Cas9 Mechanism
Core Components
The CRISPR-Cas9 system consists of the Cas9 protein, an RNA-guided endonuclease that creates a double-strand break (DSB) in DNA, and the guide RNA (gRNA), a roughly 20-nucleotide sequence complementary to the target DNA that directs Cas9 to the precise genomic location. The PAM sequence (protospacer adjacent motif), an NGG trinucleotide required adjacent to the target site for SpCas9 recognition, limits but does not severely restrict targeting options. Following the double-strand break, cellular repair proceeds through one of two pathways: non-homologous end joining (NHEJ), which is error-prone and creates insertions or deletions (indels) useful for gene disruption, or homology-directed repair (HDR), which uses a donor template for precise gene correction but is less efficient and occurs primarily in dividing cells.
Key Advantages
CRISPR's programmability allows targeting of any genomic sequence by simply changing the gRNA without requiring protein engineering. It achieves higher editing rates than prior technologies such as zinc finger nucleases (ZFNs) and TALENs. Multiplexing capability allows multiple gRNAs to target several loci simultaneously. The system is relatively inexpensive to design and produce compared to protein-based editing platforms.
Beyond Standard CRISPR-Cas9
Base Editing
Cytosine base editors (CBEs) convert C-G base pairs to T-A without creating a double-strand break, while adenine base editors (ABEs) convert A-T to G-C. The absence of a DSB means reduced risk of indels, large deletions, and chromosomal rearrangements. Base editors are limited to transition mutations (C-to-T and A-to-G) and cannot make all possible base changes. Their therapeutic relevance is substantial for correcting point mutations responsible for many genetic diseases, such as the sickle cell HbS variant which is correctable with ABE-mediated editing of the antisense strand.
Prime Editing
Prime editing functions as a "search and replace" system that can make all 12 types of point mutations as well as small insertions and deletions. It uses a Cas9 nickase fused to a reverse transcriptase guided by a prime editing guide RNA (pegRNA). No DSB and no donor DNA template are required. Currently, prime editing achieves lower efficiency than base editing in many contexts, with active optimization ongoing.
Epigenome Editing
Catalytically dead Cas9 (dCas9) fused to transcriptional activators (CRISPRa) or repressors (CRISPRi) can modulate gene expression without altering the DNA sequence. This approach has potential for treating conditions caused by gene misregulation without making permanent genomic changes.
Alternative CRISPR Systems
Cas12a (Cpf1) has different PAM requirements and creates staggered cuts, making it useful for certain applications. Cas13 targets RNA rather than DNA, offering potential for transient gene silencing without permanent genome modification. Compact Cas variants such as CasMINI and Cas12f are smaller proteins that fit within AAV packaging limits for in vivo delivery, addressing one of the field's major size constraints.
Clinical Applications
Exa-cel (Casgevy): First FDA-Approved CRISPR Therapy
Approved in December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia, exa-cel works through ex vivo CRISPR editing of patient hematopoietic stem cells to disrupt the BCL11A erythroid enhancer. BCL11A disruption reactivates fetal hemoglobin (HbF) production, which compensates for defective adult hemoglobin. The process involves HSC collection, CRISPR editing ex vivo, myeloablative conditioning with busulfan, and reinfusion of edited cells. Clinical results showed that the majority of sickle cell patients were free of vaso-occlusive crises for over 12 months post-treatment, and beta-thalassemia patients achieved transfusion independence.
In Vivo CRISPR Therapies in Clinical Trials
NTLA-2001 from Intellia represents in vivo CRISPR editing targeting TTR in hepatocytes for hereditary transthyretin amyloidosis, using lipid nanoparticle delivery of Cas9 mRNA and gRNA, and has demonstrated over 90% reduction in serum TTR levels. EDIT-101 involves in vivo subretinal delivery of AAV-packaged CRISPR components for CEP290-associated Leber congenital amaurosis 10, removing an intronic mutation to restore normal splicing. Verve Therapeutics' VERVE-101 is a base editing trial targeting PCSK9 for heterozygous familial hypercholesterolemia via a single intravenous infusion to inactivate PCSK9 in the liver.
| CRISPR Modality | Mechanism | DSB Required? | Capabilities | Limitations |
|---|---|---|---|---|
| Standard Cas9 | Creates DSB; repair via NHEJ or HDR | Yes | Gene disruption (NHEJ); precise correction with donor (HDR) | Off-target DSBs; large deletions; low HDR in non-dividing cells |
| Base editing (CBE/ABE) | Deaminase converts single bases (C→T or A→G) | No (nick only) | Transition point mutations; reduced indel risk | Limited to C→T and A→G; bystander editing in editing window |
| Prime editing | Reverse transcriptase writes new sequence | No (nick only) | All 12 point mutations; small insertions/deletions | Lower efficiency; large cargo |
| CRISPRa/CRISPRi | dCas9 + transcriptional activator/repressor | No | Gene expression modulation; reversible | No permanent genomic change; requires sustained expression |
| Cas13 (RNA targeting) | Cleaves RNA, not DNA | No | Transient gene silencing; no genome modification | Transient effect; collateral RNA cleavage |
| Approved/Trial Therapy | Target | Condition | Delivery | Status (2025) |
|---|---|---|---|---|
| Exa-cel (Casgevy) | BCL11A enhancer | Sickle cell disease, β-thalassemia | Ex vivo (HSC electroporation) | FDA approved (Dec 2023) |
| NTLA-2001 | TTR | Hereditary ATTR amyloidosis | In vivo (LNP to liver) | Phase 3 |
| EDIT-101 | CEP290 intronic mutation | Leber congenital amaurosis 10 | In vivo (AAV subretinal) | Phase 1/2 |
| VERVE-101 | PCSK9 (base editing) | Heterozygous FH | In vivo (LNP to liver) | Phase 1 |
Oncology Applications
CRISPR-engineered CAR-T cells achieve enhanced persistence, reduced exhaustion, and knockout of inhibitory receptors. Allogeneic "off-the-shelf" CAR-T cells use CRISPR deletion of HLA and TCR genes to prevent graft-versus-host disease and rejection. Multiplex editing of T cells aims to improve antitumor function through simultaneous modification of multiple pathways.
Delivery Challenges
Ex Vivo Delivery
Electroporation of CRISPR ribonucleoprotein (RNP) complexes into harvested cells is highly efficient and provides transient Cas9 exposure that reduces off-target risk. However, this approach is limited to cell types that can be removed, modified, and returned to the patient, primarily hematopoietic stem cells and T cells.
In Vivo Delivery
Lipid nanoparticles (LNPs) deliver Cas9 mRNA and gRNA with liver tropism and are used in NTLA-2001. AAV vectors can package the Cas9 gene and gRNA but persistent expression increases off-target risk, and size constraints limit Cas9 options. Tissue targeting beyond the liver remains a major challenge, with lung, brain, muscle, and other organs requiring novel delivery solutions. For safety, transient Cas9 expression via mRNA or RNP is preferred over stable expression from integrating vectors.
Safety Concerns
Off-Target Editing
Cas9 can create double-strand breaks at genomic sites with partial homology to the gRNA, potentially activating oncogenes or inactivating tumor suppressors. Detection methods include GUIDE-seq, CIRCLE-seq, Digenome-seq, and DISCOVER-seq. High-fidelity Cas9 variants such as eSpCas9 and HiFi Cas9 reduce off-target activity. Base and prime editors have lower off-target DNA editing but may have RNA off-target effects.
On-Target Unintended Effects
Large deletions and complex rearrangements at the on-target site have been documented. Chromothripsis-like events at DSB sites are a concern with nuclease-based editing. The p53-mediated DNA damage response triggered by DSBs means that cells with impaired p53 may be preferentially selected during editing, raising oncogenesis concerns.
Immunogenicity
Pre-existing antibodies and T cells against SpCas9, derived from a common human commensal bacterium, have been detected in approximately 60-70% of humans. This may limit efficacy of in vivo delivery and preclude repeat dosing. Strategies to address immunogenicity include immunosuppression, alternative Cas proteins from non-human-associated bacteria, and transient expression to minimize immune exposure.
Long-Term Monitoring
Permanent genomic changes necessitate lifelong follow-up. The FDA requires 15-year follow-up for gene therapy and gene editing products. Cancer surveillance is warranted given the theoretical oncogenesis risk from off-target editing or clonal selection.
Clinical Pearls
Exa-cel (Casgevy) represents the first approved CRISPR therapy, demonstrating that gene editing can achieve durable clinical benefit in sickle cell disease and beta-thalassemia through fetal hemoglobin reactivation. Base editing and prime editing offer precision correction without double-strand breaks, potentially reducing the safety concerns associated with standard CRISPR-Cas9 including large deletions and chromosomal rearrangements. In vivo CRISPR delivery via lipid nanoparticles has shown remarkable efficacy for liver-targeted conditions, and expanding delivery to other tissues is the major translational challenge of the coming decade. All CRISPR therapies require comprehensive off-target analysis and long-term safety monitoring given the permanent nature of genomic modifications.
References
- Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. New England Journal of Medicine. 2021;384(3):252-260.
- Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine. 2021;385(6):493-502.
- Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-157.
- Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.